News Release

Co-Diagnostics, Inc. Announces Participation in Research Project with Stanford University

CoPrimers™ used in proof of concept evaluation

SALT LAKE CITY--(BUSINESS WIRE)--Jun. 1, 2018-- Co-Diagnostics, Inc. (NASDAQ: CODX), a diagnostics company with a unique, proprietary platform for the development of molecular diagnostics, announced today that the Company’s CoPrimer™ technology is being employed to achieve the objectives of a research project conducted by the Wang Group at Stanford University.

The purpose of the study is to develop more efficient methods to detect multiple genetic mutations in the EGFR (epidermal growth factor receptor) gene, including the most frequently occurring mutations in lung cancer, within a single reaction. The investigators have been conducting research into the subject using commercially available primers for several years, the results of which have previously been published, and contacted Co-Diagnostics to utilize the Company’s technology to further improve comprehensive detection methods of mutations that are known to cause cancer. It is anticipated that the results of the current study will be compiled and published later in 2018.

Co-Diagnostics CEO Dwight Egan remarked: “We were honored that the Wang Group at Stanford University approached Co-Diagnostics and expressed interest in applying our CoPrimer technology to their endeavors to improve detection of cancer. The ability to multiplex within a single reaction, along with the heightened specificity and allowing for a massive reduction in false positives, are some of the most valuable benefits of this technology, making it ideal for cancer detection and liquid biopsy applications. The continued results of this study will help to further advance the capabilities of our technology and lay the groundwork for products to service these fast-growing markets.”

About Co-Diagnostics, Inc.:

Co-Diagnostics, Inc., a Utah corporation, is a molecular diagnostics company that has developed and intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules (DNA or RNA), and to sell diagnostic equipment from other manufacturers as self-contained lab systems.

Forward-Looking Statements:

This press release contains forward-looking statements.Forward-looking statements can be identified by words such as "believes," "expects," "estimates," "intends," "may," "plans," "will" and similar expressions, or the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements are made and predictions as to future facts and conditions.Readers of this press release are cautioned not to place undue reliance on any forward-looking statements.The Company does not undertake any obligation to update any forward-looking statement relating to matters discussed in this press release, except as may be required by applicable securities laws.

Source: Co-Diagnostics, Inc.

Company Contact:
Co-Diagnostics, Inc.
Andrew Benson
Co-Diagnostics Investor Relations
801-438-1036
investors@codiagnostics.com
or
Investor Contact:
Lytham Partners, LLC
Joe Diaz, Robert Blum and Joe Dorame
602-889-9700
codx@lythampartners.com